Elaut Greetje, Rogiers Vera, Vanhaecke Tamara
Department of Toxicology, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium.
Curr Pharm Des. 2007;13(25):2584-620. doi: 10.2174/138161207781663064.
Protein acetylation, catalyzed by the opposing activities of histone deacetylases (HDAC) and histone acetyltransferases, is now recognized to be an important epigenetic modulator of gene transcriptional activity and cell function. As a result of the intense search for HDAC inhibitors (HDACi) during the past fifteen years, a large number of structurally divergent classes with variable potencies and isoenzyme selectivities have been identified. They occupy an important and promising position in a number of therapeutic areas. Several HDACi are under clinical evaluation as tumor cell-selective chemotherapeutics, and show great promise for the treatment of inflammatory disorders, neurodegenerative diseases, protozoal and latent viral infections, and (fibro)proliferative disorders. Recently, it was discovered that they might be used as enhancers of differentiation in stem cell therapy, and as medium supplements that stabilize the phenotype of primary cells in culture. Next to biological activity, the pharmaceutical potential of a compound is also dependent on the adequate translation of in vitro potency into in vivo efficacy whilst maintaining an acceptable safety profile. Therefore, this review will not only address the formerly mentioned applications, but will also deal with the pharmacokinetic and toxicological properties of currently available HDACi. Several compounds exert potent activities in vitro, but have been shown to be of limited therapeutic value due to rapid biotransformation, and thus poor in vivo bioavailability. The first attempts to improve the metabolic properties of HDACi have been made and will be discussed. In contrast to conventional chemotherapeutics, HDACi exert no drastic side effects at therapeutically effective doses. Although a bulk effect on histone acetylation is observed, HDACi display a remarkable tumor cell-selective toxicity. The mechanisms underlying these cell type-dependent differences in sensitivity to HDACi-mediated effects, however, remain largely elusive.
蛋白质乙酰化由组蛋白脱乙酰酶(HDAC)和组蛋白乙酰转移酶的相反活性催化,现已被认为是基因转录活性和细胞功能的重要表观遗传调节剂。在过去十五年中,由于对HDAC抑制剂(HDACi)的深入研究,已鉴定出大量结构不同、具有不同效力和同工酶选择性的类别。它们在许多治疗领域占据着重要且有前景的地位。几种HDACi正在作为肿瘤细胞选择性化疗药物进行临床评估,并且在治疗炎症性疾病、神经退行性疾病、原生动物和潜伏病毒感染以及(纤维)增殖性疾病方面显示出巨大潜力。最近,人们发现它们可用作干细胞治疗中的分化增强剂,以及用作稳定培养中原代细胞表型的培养基补充剂。除了生物活性外,化合物的药物潜力还取决于将体外效力充分转化为体内疗效,同时保持可接受的安全性。因此,本综述不仅将探讨上述应用,还将讨论现有HDACi的药代动力学和毒理学特性。几种化合物在体外具有强大的活性,但由于快速生物转化,因此体内生物利用度差,已被证明治疗价值有限。已进行了首次改善HDACi代谢特性的尝试并将进行讨论。与传统化疗药物不同,HDACi在治疗有效剂量下不会产生剧烈的副作用。尽管观察到对组蛋白乙酰化有总体影响,但HDACi显示出显著的肿瘤细胞选择性毒性。然而,这些细胞类型对HDACi介导作用敏感性差异的潜在机制在很大程度上仍然难以捉摸。